Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 16/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | CBS | P35520 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1370449 | 0.90 | PTGDR2 (0.68) | PTGDR2 | |
| SCHEMBL1370613 | 0.89 | PTGDR2 (0.57) | PTGDR2RAB9A | |
| SCHEMBL1366789 | 0.84 | PTGDR2 (0.73) | PTGDR2MEN1KMT2ALMNAHTT | |
| SCHEMBL1369181 | 0.83 | PTGDR2 (0.70) | PTGDR2 | |
| SCHEMBL1369395 | 0.83 | PTGDR2 (0.57) | PTGDR2MEN1NPC1KMT2ARAB9A | |
| SCHEMBL1367421 | 0.83 | PTGDR2 (0.70) | PTGDR2KMT2A | |
| SCHEMBL1367192 | 0.81 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1369878 | 0.78 | PTGDR2 (0.70) | PTGDR2HTT | |
| SCHEMBL1367148 | 0.78 | ALDH1A1 (0.49) | PTGDR2MEN1KMT2ALMNA | |
| SCHEMBL1369227 | 0.78 | PTGDR2 (0.47) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288293-A1 | ISOQUINOLINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288293-A1 | ISOQUINOLINE DERIVATIVE | HRH1, HRH2, HRH4 | PTGDR2 189/4885MEN1 3995/4885NPC1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.